Stemline Therapeutics, Inc. (STML)
-NasdaqCM 15.94 
0.31(1.91%) 3:26PM EDT - Nasdaq Real Time Price
| Prev Close: | 16.25 |
|---|
| Open: | 15.76 |
|---|
| Bid: | 15.50 x 100 |
|---|
| Ask: | 16.00 x 300 |
|---|
| 1y Target Est: | 22.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 15.29 - 16.99 |
|---|
| 52wk Range: | 10.33 - 16.99 |
|---|
| Volume: | 42,467 |
|---|
| Avg Vol (3m): | 35,718 |
|---|
| Market Cap: | 55.02M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.82 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Thu 1:26PM EDT)
- 3 Health Care Stocks Rising on Big Volumeat TheStreet(Mon, Apr 29)
- Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013GlobeNewswire(Thu, Apr 25)
- Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, JapanGlobeNewswire(Mon, Apr 8)
- STEMLINE THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, Apr 5)
- STEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Mon, Apr 1)
- Stemline Therapeutics Reports Year-End 2012 Financial ResultsGlobeNewswire(Mon, Apr 1)
- STEMLINE THERAPEUTICS INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- STEMLINE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Mar 29)
- Fuld Disclosureat The Wall Street Journal(Mon, Mar 25)
- Boise Cascade Isn’t Recommended and 2 More Analyst Notes to Know Aboutat Wall St. Cheat Sheet(Mon, Mar 18)
- Coverage initiated on Stemline Therapeutics by Aegis CapitalBriefing.com(Mon, Mar 18)
- Stemline Therapeutics to Present at the 25th Annual Roth Conference on March 20, 2013GlobeNewswire(Tue, Mar 12)
- Stemline Therapeutics to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013GlobeNewswire(Wed, Feb 27)
- Stemline Therapeutics to Present at Leerink Swann and Company Global Healthcare ConferenceGlobeNewswire(Tue, Feb 12)
Reports
- No Reports available for STML at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-12)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk.
View More